biuro@scopefluidics.com
+48 22 376 21 14
About
Team
Our offer
Knowledge base
News
Investor relations
Career
Contact
biuro@scopefluidics.com
+48 22 376 21 14
About
Team
Our offer
Knowledge base
News
Investor relations
Career
Contact
biuro@scopefluidics.com
+48 22 376 21 14
RAPORT ESPI 1/2023 | 12-01-2023 | Zatwierdzenie prospektu Emitenta przez KNF
Previous Post
RAPORT EBI 1/2023 | 02-01-2023| Zmiana adresu
Next Post
RAPORT ESPI 2/2023 | 13-01-2023 I Złożenie wniosku do GPW o dopuszczenie i wprowadzenie akcji Emitenta do obrotu na rynku regulowanym GPW oraz o wykluczenie akcji Emitenta z obrotu na NewConnect
0
Shares
Related Posts
30.09.2026
Scope Fluidics after the first half of 2026: strong cash position, IVDR certification and expanding cooperation with distributors
SCOPE FLUIDICS
0
28.09.2026
Hybolic signs PARP funding agreement to develop a system for measuring insulin and glucose concentrations
SCOPE FLUIDICS
0
08.09.2026
Scope Fluidics Secures Another U.S. Patent for the BACTEROMIC System
SCOPE FLUIDICS
0
